Cancer's hidden switch may sit in the cell membrane, forcing growth receptors into permanent overdrive

Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment ...
ascopubs.org

Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...

A newly identified RNA target could make EGFR drugs work better against glioblastoma

Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside ...
Healio

EGFR-Mutated Non-Small Cell Lung Cancer

NSCLC is the most frequent histological subtype of lung cancer, accounting for approximately 85% of patients with lung cancer. NSCLC includes a variety of different lung cancers, most notably ...
The Manila Times

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

CStone Pharmaceuticals ('CStone,' HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...
Healio

First-line Therapy

Treatment varies based on the patient's functional status, comorbidities and tumor stage, as well as the molecular characteristics of the disease. While patients who have stage I, II or III non-small ...

Lung Cancer Research Foundation Grants Team Science Award Focused on Curing EGFR-Mutant Lung Cancers

The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...